Yeahbutt.....that was stated in August 2011.....long before we ran into the buyout vs. GIA approach....certainly management was preoccupied with those issues, as well as NCE and patents, which easily could have let their attention wander away from overseeing the trial enrollments? Or are the clinics actually running the trials responsible for finding patients? If so, are they dependent on constant funding from AMRN to keep going forward, which I assume is true? If we ran into a cash crunch, and give that loan-shark deal we got from Pharmakon, maybe the clinics were directed to slow down, we can't afford this right now? I'm totally in the dark about how these trials are actually run in that manner, but I don't think what I suggested above is out of the question either, but would certainly like to be convinced otherwise, of course!
News 
Market Data 
Discover 
AI
